The US Food and Drug Administration has received more than 1,100 comments and heard arguments from competing interests including drug firms, the supplement industry and the research community about whether to allow cannabis-based substances as dietary ingredients.
For its part, the agency has been clear that a potential for impact on developing drugs with cannabis-derived substances will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?